Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TEK
REST API REST API
Homo sapiens
TEK is differentially expressed in 246 experiments: 157 organism parts: lung, bone marrow, ... (155 more);, 231 disease states: normal, lung adenocarcinoma, ... (229 more);, 82 cell types 200 cell lines 21 compound treatments and 68 other conditions.
Synonyms TIE-2, VMCM, VMCM1, TIE2, CD202b
Orthologs tie2 (Danio rerio)   Tek (Rattus norvegicus)   F6XRE1_CIOIN (Ciona intestinalis)   TEK (Gallus gallus)   Tek (Mus musculus)   TIE2_BOVIN (Bos taurus)   Cad96Ca (Drosophila melanogaster)   tek (Xenopus laevis)   Q9MYX5_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, plasma membrane, protein binding, cell-cell adhesion, microvillus, membrane, protein tyrosine kinase activity, cell-cell signaling, blood coagulation, membrane raft, anti-apoptosis, transmembrane receptor protein tyrosine kinase signaling pathway, basolateral plasma membrane, protein oligomerization, hemopoiesis, ATP binding, cell-matrix adhesion, integral to plasma membrane, regulation of cell migration, receptor activity, nucleotide binding, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, apical plasma membrane, integral to membrane, cell surface, signal transduction, protein kinase activity, positive regulation of peptidyl-serine phosphorylation, positive regulation of cell adhesion, regulation of angiogenesis, leukocyte migration, positive regulation of ERK1 and ERK2 cascade, response to retinoic acid, positive regulation of protein kinase B signaling cascade, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, Ig-like, EGF_3, EGF-like, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom, Fibronectin_type3, Tyr_kin_Tie2_Ig-like_dom-1_N
UniProt Accession Q02763, E5RIV9, E7EWI2, D9MND0, D9MND2
Gene-Disease Assocation VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL; VMCM
Search EB-eye ENSG00000120156
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, ... (30 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-19639, E-GEOD-5823, E-GEOD-20081, E-GEOD-3529
DU145
2
E-GEOD-17482, E-GEOD-20089
WI38
2
E-MTAB-37, E-MTAB-62
HeLa
1
2
E-MTAB-62, E-GEOD-20081, E-GEOD-5823
immortalized hMSC-TERT
1
E-MEXP-560
Hec50co
1
E-GEOD-20854
194 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-13987, ... (43 experiments)

Factor Value U/D Experiments
stromal cell
3
E-MEXP-2034, E-GEOD-1460, E-GEOD-10797
endothelial cell
1
3
E-GEOD-96, E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
CD4+ T cell
2
E-MTAB-24, E-MTAB-25
fibroblast
1
2
E-GEOD-3920, E-MEXP-466, E-GEOD-26672
neuroblastoma cell
1
E-MEXP-669
secretory cell
1
E-GEOD-3998
76 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (65 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-GEOD-2514, E-MEXP-231, E-MTAB-37, E-MTAB-62
dermatomyositis
2
E-MTAB-62, E-GEOD-5370
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
prostate carcinoma
1
2
E-MTAB-62, E-GEOD-96, E-MEXP-2034
225 more value(s).


Compound treatment

studied in E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-GEOD-5339, E-GEOD-5418, ... (13 experiments)

Factor Value U/D Experiments
chloroguine
1
1
E-GEOD-5418
Cxcl12
1
1
E-GEOD-7307
not specified
1
E-GEOD-20081
unknown
1
E-GEOD-7307
TGF
1
1
E-GEOD-15205
glutamine
1
E-MEXP-1335
15 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-20847, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-5681, E-MEXP-2657, E-TABM-127, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-1926, E-TABM-666, E-GEOD-19519, E-GEOD-6919, ... (23 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-7540, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-4922

Processing time: 0.34 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM